Cargando…
Acceptance, safety and immunogenicity of a booster dose of inactivated SARS-CoV-2 vaccine in adults with tuberculosis
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
The British Infection Association. Published by Elsevier Ltd.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9867801/ https://www.ncbi.nlm.nih.gov/pubmed/36693568 http://dx.doi.org/10.1016/j.jinf.2023.01.030 |
| _version_ | 1784876422797459456 |
|---|---|
| author | Zhan, Haoting Yang, Li Liu, Yongmei Li, Haolong Li, Xiaomeng Wang, Haibin Cao, Jinfeng Kang, Shuhui Guo, Xinru Dai, Erhei Li, Yongzhe |
| author_facet | Zhan, Haoting Yang, Li Liu, Yongmei Li, Haolong Li, Xiaomeng Wang, Haibin Cao, Jinfeng Kang, Shuhui Guo, Xinru Dai, Erhei Li, Yongzhe |
| author_sort | Zhan, Haoting |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9867801 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | The British Infection Association. Published by Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-98678012023-01-23 Acceptance, safety and immunogenicity of a booster dose of inactivated SARS-CoV-2 vaccine in adults with tuberculosis Zhan, Haoting Yang, Li Liu, Yongmei Li, Haolong Li, Xiaomeng Wang, Haibin Cao, Jinfeng Kang, Shuhui Guo, Xinru Dai, Erhei Li, Yongzhe J Infect Letter to the Editor The British Infection Association. Published by Elsevier Ltd. 2023-05 2023-01-22 /pmc/articles/PMC9867801/ /pubmed/36693568 http://dx.doi.org/10.1016/j.jinf.2023.01.030 Text en © 2023 The British Infection Association. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Letter to the Editor Zhan, Haoting Yang, Li Liu, Yongmei Li, Haolong Li, Xiaomeng Wang, Haibin Cao, Jinfeng Kang, Shuhui Guo, Xinru Dai, Erhei Li, Yongzhe Acceptance, safety and immunogenicity of a booster dose of inactivated SARS-CoV-2 vaccine in adults with tuberculosis |
| title | Acceptance, safety and immunogenicity of a booster dose of inactivated SARS-CoV-2 vaccine in adults with tuberculosis |
| title_full | Acceptance, safety and immunogenicity of a booster dose of inactivated SARS-CoV-2 vaccine in adults with tuberculosis |
| title_fullStr | Acceptance, safety and immunogenicity of a booster dose of inactivated SARS-CoV-2 vaccine in adults with tuberculosis |
| title_full_unstemmed | Acceptance, safety and immunogenicity of a booster dose of inactivated SARS-CoV-2 vaccine in adults with tuberculosis |
| title_short | Acceptance, safety and immunogenicity of a booster dose of inactivated SARS-CoV-2 vaccine in adults with tuberculosis |
| title_sort | acceptance, safety and immunogenicity of a booster dose of inactivated sars-cov-2 vaccine in adults with tuberculosis |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9867801/ https://www.ncbi.nlm.nih.gov/pubmed/36693568 http://dx.doi.org/10.1016/j.jinf.2023.01.030 |
| work_keys_str_mv | AT zhanhaoting acceptancesafetyandimmunogenicityofaboosterdoseofinactivatedsarscov2vaccineinadultswithtuberculosis AT yangli acceptancesafetyandimmunogenicityofaboosterdoseofinactivatedsarscov2vaccineinadultswithtuberculosis AT liuyongmei acceptancesafetyandimmunogenicityofaboosterdoseofinactivatedsarscov2vaccineinadultswithtuberculosis AT lihaolong acceptancesafetyandimmunogenicityofaboosterdoseofinactivatedsarscov2vaccineinadultswithtuberculosis AT lixiaomeng acceptancesafetyandimmunogenicityofaboosterdoseofinactivatedsarscov2vaccineinadultswithtuberculosis AT wanghaibin acceptancesafetyandimmunogenicityofaboosterdoseofinactivatedsarscov2vaccineinadultswithtuberculosis AT caojinfeng acceptancesafetyandimmunogenicityofaboosterdoseofinactivatedsarscov2vaccineinadultswithtuberculosis AT kangshuhui acceptancesafetyandimmunogenicityofaboosterdoseofinactivatedsarscov2vaccineinadultswithtuberculosis AT guoxinru acceptancesafetyandimmunogenicityofaboosterdoseofinactivatedsarscov2vaccineinadultswithtuberculosis AT daierhei acceptancesafetyandimmunogenicityofaboosterdoseofinactivatedsarscov2vaccineinadultswithtuberculosis AT liyongzhe acceptancesafetyandimmunogenicityofaboosterdoseofinactivatedsarscov2vaccineinadultswithtuberculosis |